CBS 2019
CBSMD教育中心
中 文

Stenting Left Main

Abstract

Recommended Article

Left-main restenosis in the DES era-a call for action Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial New-onset atrial fibrillation after PCI and CABG for left main disease: insights from the EXCEL trial and additional studies Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention Radial versus femoral artery access in patients undergoing PCI for left main coronary artery disease: analysis from the EXCEL trial Outcomes of patients with and without baseline lipid-lowering therapy undergoing revascularization for left main coronary artery disease: analysis from the EXCEL trial Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial

Review Article 2017 Nov 10 [Epub ahead of print]

JOURNAL:Cardiovasc Revasc Med. Article Link

Left-main restenosis in the DES era-a call for action

di Palma G, Cortese B Keywords: In-stent restenosis; Sirolimus-coated balloon; Unprotected left main

ABSTRACT

Percutaneous treatment of the unprotected left main trunk (ULM), defined as a vessel without patent bypass graft either to the left circumflex (LCX) or left anterior descending (LAD) artery, has gained a precise role thanks to recent scientific evidence. Although new generation drug-eluting stents have already proven to be safer, there is still a consistent risk of restenosis and late adverse events. The optimal management of a ULM restenosis is still debated. Here we aim at presenting a review of the available data in literature and show our choice for treating it.